Patents by Inventor John C. Herr
John C. Herr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11904068Abstract: Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.Type: GrantFiled: February 17, 2022Date of Patent: February 20, 2024Assignee: University of Virginia Patent FoundationInventors: John C. Herr, Alexander L. Klibanov, Kevin Simon Eisenfrats
-
Publication number: 20230027709Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.Type: ApplicationFiled: November 16, 2020Publication date: January 26, 2023Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: John C. HERR, Monika SACHDEV, Arabinda MANDAL
-
Publication number: 20220168461Abstract: Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.Type: ApplicationFiled: February 17, 2022Publication date: June 2, 2022Inventors: John C. Herr., Alexander L. Klibanov, Kevin Simon Eisenfrats
-
Patent number: 11278641Abstract: Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.Type: GrantFiled: October 29, 2018Date of Patent: March 22, 2022Assignee: University of Virginia Patent FoundationInventors: John C. Herr, Alexander L. Klibanov, Kevin Simon Eisenfrats
-
Publication number: 20210269549Abstract: The present disclosure provides anti-SAS1B antibodies, antigen-binding fragments thereof, and antibody-drug conjugates and methods of their use. This present disclosure also provides an isolated antibody or antigen-binding portion thereof having at least one of SB antibodies binding to surface exposed SAS1B, and 6B1 antibodies identifying at least one set of cancer patients testing positive for SAS1B expression.Type: ApplicationFiled: December 29, 2020Publication date: September 2, 2021Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: John C. HERR, Eusebio PIRES, Ryan D'SOUZA, Arabinda MANDAL, Kiley ANDERSON-KNAPP
-
Publication number: 20190194345Abstract: The present disclosure provides anti-SAS1B antibodies, antigen-binding fragments thereof, and antibody-drug conjugates and methods of their use. This present disclosure also provides an isolated antibody or antigen-binding portion thereof having at least one of SB antibodies binding to surface exposed SAS1B, and 6B1 antibodies identifying at least one set of cancer patients testing positive for SAS1B expression.Type: ApplicationFiled: October 5, 2016Publication date: June 27, 2019Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: John C. HERR, Eusebio PIRES, Ryan D'SOUZA, Arabinda MANDAL, Kiley ANDERSON-KNAPP
-
Publication number: 20190060513Abstract: Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.Type: ApplicationFiled: October 29, 2018Publication date: February 28, 2019Inventors: John C. Herr, Alexander L. Klibanov, Kevin Simon Eisenfrats
-
Patent number: 10155063Abstract: Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.Type: GrantFiled: November 11, 2016Date of Patent: December 18, 2018Assignee: University of Virginia Patent FoundationInventors: John C. Herr, Alexander L. Klibanov, Kevin Simon Eisenfrats
-
Publication number: 20180326088Abstract: The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.Type: ApplicationFiled: July 23, 2018Publication date: November 15, 2018Applicant: University of Virginia Patent FoundationInventors: John C. Herr, Eusebio S. Piers, Austin Herr
-
Publication number: 20180066052Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.Type: ApplicationFiled: August 7, 2017Publication date: March 8, 2018Applicant: University of Virginia Patent FoundationInventors: John C. Herr, Monika Sachdev, Arabinda Mandal
-
Patent number: 9803012Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.Type: GrantFiled: May 23, 2012Date of Patent: October 31, 2017Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: John C. Herr, Monika Sachdev, Arabinda Mandal
-
Publication number: 20170298141Abstract: The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.Type: ApplicationFiled: April 28, 2017Publication date: October 19, 2017Applicant: University of Virginia Patent FoundationInventors: John C. Herr, Eusebio S. Pires, Austin Herr
-
Publication number: 20170136143Abstract: Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.Type: ApplicationFiled: November 11, 2016Publication date: May 18, 2017Inventors: John C. Herr, Alexander L. Klibanov, Kevin Simon Eisenfrats
-
Publication number: 20170136144Abstract: Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.Type: ApplicationFiled: November 11, 2016Publication date: May 18, 2017Inventors: John C. Herr, Alexander L. Klibanov, Kevin Simon Eisenfrats
-
Publication number: 20160195538Abstract: The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor, is also expressed in various cancers, including ovarian cancer and uterine cancer. Six SAS1R variants have been previously identified, and they are encompassed by the invention. The present invention further provides antibodies useful for targeting SAS1R expressing cells and for killing such cells.Type: ApplicationFiled: December 28, 2015Publication date: July 7, 2016Inventors: John C. Herr, Eusebio S. Pires
-
Patent number: 9244075Abstract: The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor, is also expressed in various cancers, including ovarian cancer and uterine cancer. Six SAS1R variants have been previously identified, and they are encompassed by the invention. The present invention further provides antibodies useful for targeting SAS1R expressing cells and for killing such cells.Type: GrantFiled: August 8, 2011Date of Patent: January 26, 2016Assignee: University of Virginia Patent FoundationInventors: John C. Herr, Euseblo S. Pires
-
Publication number: 20150125445Abstract: The present invention provides compositions for targeting SAS1B positive cancer cells using immunotoxin technology and discloses that kidney and pancreatic cancer cells are SAS1B positive, but not normal kidney and pancreatic cells. The invention discloses that despite being expressed only in growing oocytes in females among normal tissues SAS1B is expressed in cancers of both men and women.Type: ApplicationFiled: June 13, 2013Publication date: May 7, 2015Inventors: John C. Herr, Eusebio S. Pires, Austin Herr
-
Publication number: 20130164215Abstract: The present invention provides compositions and methods useful for diagnosing, treating, and preventing cancer, particularly ovarian cancer and uterine cancer, based on the discovery that the oocyte specific protein, SAS1R (Sperm Acrosomal SLL-P1 Receptor), which is a sperm protein receptor, is also expressed in various cancers, including ovarian cancer and uterine cancer. Six SAS1R variants have been previously identified, and they are encompassed by the invention. The present invention further provides antibodies useful for targeting SAS1R expressing cells and for killing such cells.Type: ApplicationFiled: August 8, 2011Publication date: June 27, 2013Applicant: University of Virginia Patent Foundation,d/b/a University of Virginia Licensing & VenturesGroupInventors: John C. Herr, Eusebio S. Pires
-
Publication number: 20120252031Abstract: The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females.Type: ApplicationFiled: May 23, 2012Publication date: October 4, 2012Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: John C. Herr, Monika Sachdev, Arabinda Mandal
-
Patent number: 7947026Abstract: A method and device to conform with the glans penis to recover ejaculated semen completely, to prevent the loss of initial sperm rich epididymal fractions, to avoid the use of a condom for masturbation, to eliminate the multi-step transfers of semen following ejaculation that are common with current methods, and to provide a single device that contains a semen collecting chamber that fits onto a glans penis. The device provides a storage and measuring reservoir, an optional cap, and a vertical stand in one integrally formed module in a sterile pack. The device and method will have multiple uses in a variety of contexts including, but not limited thereto: in the diagnosis of infertility, in semen donation, in vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) clinics, hospitals, forensic laboratories and research laboratories and will be included in kits intended for over-the-counter sperm testing devices.Type: GrantFiled: November 5, 2004Date of Patent: May 24, 2011Assignee: University of Virginia Patent FoundationInventors: John C. Herr, Arabinda Mandal